Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$42.30

-4.62 (-9.85%)

18:01
06/04/18
06/04
18:01
06/04/18
18:01

Tesaro says Zejula data 'promising'

Tesaro summarized the results of the TOPACIO and QUADRA trials during an investor briefing held in conjunction with the 2018 American Society of Clinical Oncology Annual Meeting. "The promising data presented at this year's ASCO meeting demonstrated the potential of ZEJULA not only as a monotherapy treatment for women with advanced ovarian cancer, but also in combination with an anti-PD-1 antibody, to provide a meaningful clinical benefit to patients beyond those with BRCA mutations," said Mary Lynne Hedley, Ph.D., President and COO of TESARO. "Our oncology development strategy is focused on rational therapeutic combinations and niraparib and TSR-042, our anti-PD-1 antibody, are the foundation of this strategy. The TOPACIO results support the advancement of combination studies in ovarian cancer and breast cancers and we have initiated preparations for registrational trials of niraparib in combination with TSR-042 in these settings. QUADRA results demonstrated that ZEJULA is active as a late-line treatment for patients beyond those with BRCA mutations, which is the only treatment setting in which PARP inhibitors are approved today, and we intend to submit an sNDA in the fourth quarter of 2018."

  • 04

    Jun

TSRO Tesaro
$42.30

-4.62 (-9.85%)

05/03/18
PIPR
05/03/18
NO CHANGE
Target $50
PIPR
Neutral
Tesaro price target lowered to $50 from $60 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond lowered his price target on Tesaro to $50, saying that while Q1 results were "solid" thanks to a Zejula beat, the limited visibility around the geographic mic and below-consensus outlook for Q2 will keep shares under pressure. The analyst kept his Neutral rating on Tesaro, adding that the increasing interchangeability of the marketed PARP inhibitors and a potential safety disadvantage for Zejula could further drag on the uptake, pressuring FY18 guidance.
05/07/18
LSCM
05/07/18
NO CHANGE
Target $80
LSCM
Buy
Tesaro price target lowered to $80 from $120 at Lake Street
Lake Street analyst Bruce Jackson lowered his price target for Tesaro to $80 saying the company reported "disappointing" Q1 results. The analyst was hoping for more of a rebound in Zejula growth but notes the "tepid" Q2 revenue guide "suggests otherwise. He lowered his 2018 revenue estimate to $279M from $322M but keeps a Buy rating on Tesaro shares.
05/30/18
JEFF
05/30/18
NO CHANGE
Target $48
JEFF
Hold
Tesaro risk/reward 'skewed toward downside,' says Jefferies
Jefferies analyst Eun Yang believes Tesaro's (TSRO) risk/reward is "skewed toward downside" into AstraZeneca's (AZN) Phase 3 ovarian cancer data for Lynparza . A discussion with a key opinion leader points to high bar for clinical/commercial success, Yang tells investors in a research note. She points out that Zejula in first-line ovarian cancer accounts for greater than 40% of her $48 price target for Tesaro. The analyst keeps a Hold rating on the shares.
05/31/18
SBSH
05/31/18
NO CHANGE
Target $100
SBSH
Buy
Amid investor questions, Citi reiterates $100 target on Tesaro
Citi analyst Robyn Karnauskas says she's been getting a lot of investor questions on Tesaro (TSRO) around the impact of Avastin approval on PARP use in first-line ovarian cancer, ahead of AstraZeneca's (AZN) Solo-1 data expected in the first half of 2018. After speaking to Tesaro's CEO, the analyst continues to be constructive on the quarter. The company believes that eventually Avastin will mostly be used in combinations, Karnauskas tells investors in a research note. She thinks Tesaro shares "will emerge" with crucial data expected in the latter half of the year. The analyst reiterates a Buy rating on the shares with a $100 price target.

TODAY'S FREE FLY STORIES

ADS

Alliance Data

$218.91

-24.58 (-10.09%)

, LB

L Brands

$32.01

0.31 (0.98%)

07:32
07/17/18
07/17
07:32
07/17/18
07:32
Hot Stocks
Columbus signs renewal agreement with Victoria's Secret »

Alliance Data Systems…

ADS

Alliance Data

$218.91

-24.58 (-10.09%)

LB

L Brands

$32.01

0.31 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

PRIM

Primoris

$28.12

-0.51 (-1.78%)

07:32
07/17/18
07/17
07:32
07/17/18
07:32
Hot Stocks
Primoris announces electrical distribution award valued over $75M »

Primoris Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$41.10

1.38 (3.47%)

07:30
07/17/18
07/17
07:30
07/17/18
07:30
Recommendations
Zscaler analyst commentary  »

Zscaler price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$40.55

-4.34 (-9.67%)

, QEP

QEP Resources

$12.09

-0.67 (-5.25%)

07:30
07/17/18
07/17
07:30
07/17/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

TSRO

Tesaro

$40.55

-4.34 (-9.67%)

QEP

QEP Resources

$12.09

-0.67 (-5.25%)

HUBG

Hub Group

$49.10

-1.85 (-3.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 19

    Aug

RPM

RPM

$60.00

-0.54 (-0.89%)

07:27
07/17/18
07/17
07:27
07/17/18
07:27
Downgrade
RPM rating change  »

RPM downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

OSUR

OraSure

$16.28

-1.04 (-6.00%)

07:27
07/17/18
07/17
07:27
07/17/18
07:27
Recommendations
OraSure analyst commentary  »

OraSure weakness a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

NFLX

Netflix

$400.24

4.32 (1.09%)

07:26
07/17/18
07/17
07:26
07/17/18
07:26
Recommendations
Netflix analyst commentary  »

Canaccord views Netflix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOR

ElectroCore

$14.49

-0.51 (-3.40%)

07:25
07/17/18
07/17
07:25
07/17/18
07:25
Initiation
ElectroCore initiated  »

ElectroCore initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$30.58

-0.36 (-1.16%)

07:24
07/17/18
07/17
07:24
07/17/18
07:24
Initiation
TechnipFMC initiated  »

TechnipFMC assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

QTS

QTS Realty Trust

$40.90

-0.05 (-0.12%)

07:23
07/17/18
07/17
07:23
07/17/18
07:23
Initiation
QTS Realty Trust initiated  »

QTS Realty Trust resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

BA

Boeing

$356.01

5.2 (1.48%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Hot Stocks
Boeing signs integrated services agreement with Blackshape »

Boeing announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

NFLX

Netflix

$400.24

4.32 (1.09%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Recommendations
Netflix analyst commentary  »

Oppenheimer remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$400.24

4.32 (1.09%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INXN

Interxion

$64.05

0.77 (1.22%)

07:21
07/17/18
07/17
07:21
07/17/18
07:21
Initiation
Interxion initiated  »

Interxion resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

07:20
07/17/18
07/17
07:20
07/17/18
07:20
General news
FX Update: The Dollar remained on a softening tack »

FX Update: The Dollar…

BAESY

BAE Systems

$0.00

(0.00%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Periodicals
BAE Systems wants international partners for UK fighter project, Reuters says »

BAE Systems wants to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INAP

Internap

$11.31

-0.63 (-5.28%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Initiation
Internap initiated  »

Internap resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$138.45

-0.91 (-0.65%)

, MA

MasterCard

$204.05

-1.86 (-0.90%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Recommendations
Visa, MasterCard analyst commentary  »

Visa price target raised…

V

Visa

$138.45

-0.91 (-0.65%)

MA

MasterCard

$204.05

-1.86 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

FDC

First Data

$22.24

-0.06 (-0.27%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Recommendations
First Data analyst commentary  »

First Data price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

EQIX

Equinix

07:17
07/17/18
07/17
07:17
07/17/18
07:17
Initiation
Equinix initiated  »

Equinix resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Aug

MA

MasterCard

$204.05

-1.86 (-0.90%)

07:17
07/17/18
07/17
07:17
07/17/18
07:17
Recommendations
MasterCard analyst commentary  »

MasterCard price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

AUTL

Autolus Therapeutics

$23.00

2.11 (10.10%)

07:16
07/17/18
07/17
07:16
07/17/18
07:16
Initiation
Autolus Therapeutics initiated  »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVT

Avnet

07:15
07/17/18
07/17
07:15
07/17/18
07:15
Initiation
Avnet initiated  »

Avnet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARW

Arrow Electronics

$77.09

-0.47 (-0.61%)

07:15
07/17/18
07/17
07:15
07/17/18
07:15
Initiation
Arrow Electronics initiated  »

Arrow Electronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QURE

uniQure

$35.08

-4.41 (-11.17%)

, PFE

Pfizer

$37.39

-0.14 (-0.37%)

07:15
07/17/18
07/17
07:15
07/17/18
07:15
Recommendations
uniQure, Pfizer analyst commentary  »

uniQure pullback on…

QURE

uniQure

$35.08

-4.41 (-11.17%)

PFE

Pfizer

$37.39

-0.14 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.